Immunotherapy kills cancer cells by activating the body's own immune system, with immune checkpoint inhibitors (ICIs) being the currently preferred immunotherapy strategy, and T-cell receptor programmed cell death receptor 1 (PD-1) and ligand programmed cell death-ligand 1 (PD-L1) are the main immune checkpoint molecules applied to anticancer immunotherapy [15–17]. The gene discussed is CD274; the disease is cancer.